Abstract
Background: Rapid itch response is a desirable treatment goal for atopic dermatitis (AD). In JADE-COMPARE, more patients had clinically meaningful itch relief (≥4-point improvement in Peak Pruritus Numerical Rating Scale [PP-NRS4]) at week 2 with abrocitinib 200 mg (49.1%) vs dupilumab (26.4%) and placebo (13.8%) and with abrocitinib 100 mg (31.8%) vs placebo (all comparisons, P≤0.0002). We investigated itch response from days 2-15 and relationships between week 2 PP-NRS4 response and week 12 response of ≥90% improvement in Eczema Area and Severity Index (EASI-90).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
